

# **CURRICULUM VITAE**

7/1/10

**Name:** Jeffery A. Hobden, PhD

**Business Address:** Department of Microbiology, Immunology, & Parasitology  
LSU Health Sciences Center – New Orleans  
1901 Perdido Street  
New Orleans, LA 70112

**Business Telephone:** (504)568-4077 office  
(504)568-6114 lab

**Fax:** (504)568-2918

**E-Mail:** jhobde@lsuhsc.edu

**Home Address:** 609 Fleurie Drive  
Kenner, LA 70065

**Home Telephone:** (504)305-3568

**Home E-mail:** jhobden@msn.com

**Birthdate and Birthplace:** January 8, 1963; New Orleans, LA

**Spouse:** Xiaowen Rudner-Hobden, no children

**Citizenship:** United States of America

## **Education:**

### **Baccalaureate:**

Bachelor of Science in Biological Sciences from Loyola University, New Orleans, Louisiana in December 1985.

### **Graduate:**

Master of Science in Medical Microbiology from Louisiana State University Medical Center, New Orleans, Louisiana in August 1988.

Doctor of Philosophy in Medical Microbiology from Louisiana State University Medical Center, New Orleans, Louisiana in December 1992.

### **Post-Graduate:**

Research Fellow, Department of Ophthalmology, LSU Eye Center, New Orleans, Louisiana, 1993.

Research Associate, Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan, 1994-August 1996.

**Academic, Professional, and Research Appointments:**

Research Assistant Professor, Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan, September 1996 - January 1997.

Research Assistant Professor, Department of Anatomy and Cell Biology and Immunology and Microbiology, Wayne State University School of Medicine, Detroit, Michigan, February 1997- July 1997.

Assistant Professor, Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, Michigan, July 1997 - January 2004.

Assistant Professor, Department of Microbiology, Immunology, & Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, February 2004 – June 2010.

Associate Professor with tenure, Department of Microbiology, Immunology, & Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, July 2010 - present.

Education Facilitator and Director of the Bioscience Education & Training Program, South Louisiana Institute for Infectious Disease Research, Louisiana State University Health Sciences Center, New Orleans, Louisiana, October 2007 – present.

**Membership in Professional Organizations:**

Beta Beta Beta National Biological Honor Society, 1982-1985

American Society for Microbiology, 1987- present.

Association for Research in Vision and Ophthalmology, 1990 - present.

Master Teacher, LSUHSC Academy for the Advancement of Educational Scholarship, 2007- present.

Infectious Disease Society of America, 2008- present.

**Awards and Honors:**

1985 St. Joseph Pignatelli, S.J. Award for Excellence in Biological Sciences, Loyola University, New Orleans, Louisiana.

- 1985 Randall Award, American Society for Microbiology, South Central Branch Meeting, Lake Charles, Louisiana.
- 1987 Strawinski Award, American Society for Microbiology, South Central Branch Meeting, Hammond, Louisiana.
- 1988 Sigma Xi Research Day Award, Sigma Xi Scientific Research Society, Louisiana State University Medical Center, New Orleans, Louisiana.

**Teaching Experience/Responsibilities:**

Pre-doctoral Experience (Loyola University New Orleans, LSUMC-NO)

- 1982-1985 Student Teaching Assistant, Undergraduate Botany, Microbiology, Physiology, and Zoology, Loyola University, New Orleans, Louisiana. Semester-long responsibilities included student supervision in laboratory exercises, class and laboratory preparation, and grading exams.
- 1988 Lecturer and Laboratory Course Director, Undergraduate Microbiology, Loyola University, New Orleans, Louisiana. Responsibilities included presenting lectures and organizing laboratory exercises for a full semester.
- 1989,  
1991-1993 Lecturer, Undergraduate Microbiology, Immunology, and Parasitology, School of Nursing, Louisiana State University Medical Center, New Orleans, Louisiana. Responsibilities included preparing handouts and other lecture materials, generating exam questions.
- 1987-1993 Laboratory Instructor, Medical Microbiology, Louisiana State University Medical Center, New Orleans, Louisiana. Responsibilities included supervising sophomore medical students in the laboratory and presenting material relevant to laboratory exercises.

Experience at Wayne State University School of Medicine, Detroit, Michigan

- 1995,  
1997, 1998 Lecturer, Graduate Microbiology: Responsibilities included preparing handouts and other lecture materials, generating exam questions, administering exams.
- 1997- 2003 Lecturer and Lab Director, Medical Microbiology: Responsibilities included preparing handouts and other lecture materials, generating exam questions and assembling exams, administering exams, supervising sophomore medical students in the laboratory and presenting material relevant to laboratory exercises.
- 1998-2003 Lecturer, USMLE Step I Review: Presented a comprehensive review of infectious diseases from a systems based approach.

- 1998 Lecturer, Molecular Biology Core Course: Presented a lecture to first year graduate students in an interdisciplinary program.
- 1999-2003 Lecturer, Molecular Mechanisms of Bacterial Pathogenesis: Responsibilities included preparing handouts and other lecture materials for senior graduate students, generating exam questions and assembling exams, administering exams, calculating and reporting final grades.
- 1998-2003 Lecturer, Department of Ophthalmology's Basic and Clinical Science Series, Kresge Eye Institute, Detroit, Michigan. Presented annual lecture to ophthalmology residents on infectious keratitis.

Experience at LSU Health Sciences Center, New Orleans, LA

Fall 2004 **Lecturer and Course Director, MICRO 280 - Techniques in Microbiology:**

- Designed course to familiarize first year graduate students with commonly used techniques in molecular biology and to teach problem solving skills for biomedical research.
- Responsibilities included topic development, organizing faculty for presentations, determining final grades, preparing lecture materials (handouts and PowerPoint presentations) and a wet laboratory exercise.
- MICRO 280 has not been taught since Fall 2004 due to changes in the School of Graduate Studies curriculum.

Fall 2004

Fall 2005

Spring 2006

Spring 2007

**Lecturer, DENT 2120 (later DENT 1118) - Dental Microbiology.**

- Prepared handouts, PowerPoint presentations, and generated exam questions.
- Presided over small group discussions.
- Presented 6 hours of lecture.
- As of Spring 2008, DENT 1118 is no longer taught by MIP faculty.

Fall 2004

- present

**Lecturer, Course Director, Medical Microbiology- MICRO 200.**

- In 2004, re-organized the bacteriology component.
- Served as laboratory instructor in Fall 2004 & 2005.
- Lecture hours steadily increased from 2004 –2008: 6, 12, 14, 17, and 20 hours direct student contact.
- In Fall 2008, officially became course director.
- Responsibilities include topic development, organizing faculty for presentations, determining final grades, preparing lecture materials (handouts and PowerPoint presentations) and preparing exams.

- Course ratings by Aesculapian Society steadily improved from “poor” (2004) to “excellent” (2008).
- Increased clinical relevance of course by working with Dr. Julio Figueroa, an infectious disease physician from the LSUHSC Dept. of Medicine, and attending ID Citywide conferences twice a week.
- Cross referenced MICRO 200 material with other L2 classes (pathology and pharmacology).
- USMLE exam results (Step 1 and 2) suggest that MICRO 200 is fulfilling its purpose in training competent physicians.

Spring 2005

Spring 2006

**Lecturer, USMLE Step I Review.** I presented a comprehensive review of infectious diseases from a systems based approach for L2 students who did not pass Step 1 on the first attempt. Each review session lasted approximately 3 hours.

Spring 2006

- present

**Lecturer, Medical Pharmacology – PHARM 200.**

- Coordinate coverage of antibiotics with Dr. Julio Figueroa’s microbe-centric view of antibiotics
- Present 4 lecture hours on antibiotics.
- Very favorably reviewed by Aesculapian Society.

Summer 2006

Spring 2008-present

**Lecturer and Course Director, Advanced Medical Bacteriology – MICRO 225.**

- Possess the depth and breadth of knowledge and experience required to organize this course.
- Presented half of the lectures (24 lecture hours) 2008-2009.
- Recruited faculty for lectures in area of expertise, compiled and administered exams, and determined final grades for the course.

Fall 2007

**Lecturer and Course Director, Graduate Medical Microbiology – MICRO 221.**

- Adoption of the interdisciplinary curriculum in the School of Graduate Studies necessitated the formation of MICRO 221, an off-shoot of MICRO 200 adapted for graduate students.
- Developed this course using the framework of MICRO 200 and shifted the focus from clinical to basic science.
- Presented 12 hours of lectures.

- Recruited faculty for lectures in area of expertise, compiled and administered exams, and determined final grades for the course.
- This course was merged with MICRO 225 in Spring 2009.

Fall 2008  
- present

**Lecturer and Program Developer, Bioscience Education and Training (BET) Program, South Louisiana Institute for Infectious Disease Research (SLIIDR).**

- Developed this Louisiana Board of Regents funded program as part of the SLIIDR organization's educational mandate.
- The mission of the BET program is to provide laboratories engaged in biomedical research with qualified research associates.
- The BET program recruits undergraduates with BS degrees from area universities and community colleges and places them into 6 months of didactic lectures. Wet lab skill labs accompany many of the didactic sessions. Participants also receive mandated safety training in use of chemical, radioactive, and biological hazards. At the end of the program, job placement assistance is available.
- Responsibilities include curriculum development and implementation, recruitment and evaluation of participants, preparing and supervising laboratory exercises.
- Approximately 50 hours spent on lectures and supervising wet lab exercises

Summer 2010    **Lecturer, Selected Topics in Microbiology (Biofilms) – MICRO 281**

Summer 2010    **Lecturer, Ophthalmology and Systemic Diseases – OPHTH 300**

**Teaching Awards:**

2000, 2003    College Teaching Award, Wayne State University, Detroit, Michigan.

**Graduate Students Trained:**

Past:

- 1998-1999    Dawn J. Geisler, MS, Basic Medical Sciences, Wayne State University School of Medicine, *Pseudomonas* Proteases and Ocular Virulence.
- 1998-2001    Christopher Pillar, PhD, Department of Immunology/Microbiology, Wayne State University School of Medicine, Role of *P. aeruginosa* Exoproducts and Ocular Virulence.
- 1998-2002    Catherine D. White, PhD, Department of Immunology/Microbiology, Wayne State University School of Medicine, Role of *P. aeruginosa* Quorum Sensing Systems in Ocular Virulence.

- 2003 Robert Moldenhauer, MS, Basic Medical Sciences, Wayne State University School of Medicine, Monkeypox and the Threat of Emerging Infections.
- 2002-2005 Quinn M. Parks, PhD, Department of Immunology/Microbiology, Wayne State University School of Medicine, Genetic Determinants of *P. aeruginosa* Ocular Virulence.
- 2005-2009 Priyanka Karicherla, PhD, LSU Health Sciences Center, Nona-D-Arginine Therapy for Bacterial Keratitis.

**Thesis & Dissertation Committees:**

Past:

- 1997 Phillip Estrellas, Jr., BS, Howard Hughes Medical Institute Summer Undergraduate Research Program, *Pseudomonas aeruginosa* Exoproteases and Ocular Pathogenesis.
- 1998 Jerry Stassinopoulos, MS, Basic Medical Sciences, Wayne State University School of Medicine, How Superantigens Stimulate T Cells.
- 1998-1999 Phillip Estrellas, Jr., BS, Minority Access to Research Careers (MARC) Program, Characterization of an Ocularly Avirulent *Pseudomonas aeruginosa* Strain.
- 1999 Amanda C. Solem, BS, Senior Individualized Project, Kalamazoo College (Kalamazoo, Michigan), ICAM-2 and *P. aeruginosa* Keratitis.
- 2000-2001 Angela Chmielewski, BS, Capstone Project, Miami University (Oxford, Ohio), *P. aeruginosa* Polyphosphate and Ocular Virulence.
- 1999-2003 Lin Liu, PhD, Department of Immunology/Microbiology, Wayne State University School of Medicine, Identification and Characterization of Trans-activating Factor(s) Responsible for cAMP-mediated Mitochondrial Transcription in the Yeast *Saccharomyces cerevisiae*.
- 2000-2003 Sonya Green, PhD, Department of Immunology/Microbiology, Wayne State University School of Medicine, Characterization of PrfA-regulated Virulence Gene Expression in *Listeria monocytogenes*.
- 2001 Melphine M. Ponniah, MS, Basic Medical Sciences, Wayne State University School of Medicine, Public Health Implications of Bacterial Contamination in Recreational Water.
- 2001-2003 Yunus Moosa, PhD, Department of Immunology/Microbiology, Wayne State University School of Medicine, Investigation of Virulence and Resistance Gene Expression in *Candida albicans*: Studies on Primary Isolates from Patients with Acute Vulvovaginal Candidiasis.
- 2002-2005 George Roberts, MS, Department of Immunology/Microbiology, Wayne State University School of Medicine, RSF2 Nuclear Gene Encoding a Product Required for Respiration in the Yeast *Saccharomyces cerevisiae*.
- 2008-2009 Shauntel Adams, MS, Department of Microbiology, Immunology and Parasitology, LSU Health Sciences Center, Microsatellite Variation and its Functional Consequences in Group B Streptococci.

Current:

2007-present Lyndsey Buckner, doctoral candidate, Department of Microbiology, Immunology and Parasitology, LSU Health Sciences Center, *Chlamydia trachomatis* pathogenesis.

**Grants & Contracts:**

Funded:

- 1995-1996 Individual National Research Service Award (F32) recipient; *P. aeruginosa* exoproteases and ocular infectivity; National Eye Institute, The National Institutes of Health, EYO6548-01A2; \$30,000, direct costs.
- 1996-2001 First Independent Research Support and Transition Award (R29); *P. aeruginosa* exoproteins and ocular infectivity; National Eye Institute, The National Institutes of Health; \$350,000, direct costs. Role in Project: Principal Investigator
- 2001-2002 Midwest Eye-Banks & Transplantation Center (MEBTC) Scientific Research Award, *P. aeruginosa* RhlI/PPK and Ocular Virulence, \$14,000 direct costs. Role on Project: Principal Investigator.
- 2002-2003 Research Grant, *Pseudomonas aeruginosa* PPK and Ocular Virulence, Prevent Blindness America, \$12,000 direct costs. Role on Project: Principal Investigator.
- 2003-2006 Research Grant (Army), Real-time Biosensor Water Monitoring System, TACOM/Army, Dept. of Defense, \$2,500,000 direct costs. Role on Project: Co-Principal Investigator.
- 2003-2006 Research Grant (R21); Filamentous Influenza Virus and Microbial Colonization; National Institute of Allergy and Infectious Disease, The National Institutes of Health; \$300,000 direct costs. Role on Project: Co-Investigator.
- 2006-2007 Contract, International Health Management Associates. Tigecycline Evaluation and Surveillance Trial (Wyeth Pharmaceuticals). \$7,000 direct costs. Role on Project: Principal Investigator.
- 2007-2010 Louisiana Board of Regents (RCEEP 2). South Louisiana Institute for Infectious Disease Research. \$3,350,000 direct cost. Role on Project: Educational Facilitator. (BET Program – 50% salary covered)
- 2007 Contract, International Health Management Associates. Carbapenem Antimicrobial Susceptibility Test with Laboratory E-Test (Ortho-McNeil Pharmaceutical, Inc.). \$2,450 direct costs. Role on Project: Principal Investigator.
- 2008 Contract, International Health Management Associates. Oritavancin Susceptibility Profile Initiative. (Targanta Therapeutics, Inc.). \$3,600 direct costs. Role on Project: Principal Investigator.
- 2008 Contract, International Health Management Associates. Tigecycline Evaluation and Surveillance Trial Continuation (Wyeth Pharmaceuticals). \$7,000 direct costs. Role on Project: Principal Investigator.

2009-2011 Department of Orthopedics, LSU Health Sciences Center, Bacterial biofilms on orthotic devices. \$75,000 direct costs. Role on Project: Co-investigator.

Pending Funding:

2009 Research Grant (R01); Nano-Coated Infection-Resistant Orthopedic  
(October) Material, National Institute of Arthritis and Musculoskeletal Disease, The National Institutes of Health; \$525,000 direct costs. Role on Project: Co-Principal Investigator.

2010 Research Grant (R01); Nona-D-Arginine and Bacterial Keratitis;  
(June) National Eye Institute, The National Institutes of Health; \$525,000 direct costs. Role on Project: Principal Investigator.

Non-funded Applications (last 3 years):

2007-2010 Research Grant, Methods to Increase Hand Hygiene and Decrease  
Nosocomial Transmission; Centers for Disease Control; \$655,000 direct costs. Role on Project: Co-Investigator.

2007-2010 Research Grant (R01); Nona-D-Arginine Therapy of *Pseudomonas aeruginosa* Corneal Disease; National Eye Institute, The National Institutes of Health; \$650,000 direct costs. Role on Project: Principal investigator.

2009 Research Grant; Infection-Resistant Orthopedic Material; Extremity War Trauma Research Foundation; \$200,000 direct costs. Role on Project: Co-investigator.

Research Interests and Collaborations

1. Therapies for Methicillin-Resistant *Staphylococcus aureus* Keratitis; collaboration with James Hill, Ph.D.; LSUHSC Dept. of Ophthalmology, 2009-present.
2. Antibiotic Delivery to the Cornea by Lacrimal Inserts; collaboration with Jean Jacob, PhD; LSUHSC Dept. of Ophthalmology, 2009-present.
3. Stable Curcumin Solutions as Antimicrobial Agents; collaboration with Zhijun Liu, Ph.D., Medicinal Plant Lab, LSU Agricultural Center, 2008 – 2009.
4. Infection-Resistant Orthopedic Material; collaboration with Mandy Lopez, DVM, MS, PhD, LSU School of Veterinary Medicine; Daniel Hayes, PhD; Michael Murphy, PhD, and Todd Monroe, PhD, LSU, 2009-present.

Research Review Committee:

1999-2001 Grant reviewer, Prevent Blindness America, Fight for Sight Research Awards Program, Chicago, Illinois.

2009 Grant reviewer, U.S. Civilian Research & Development Foundation (CRDF), Cooperative Grants Program, Arlington, Virginia.

## **Papers Presented:**

### **Scientific Presentations:**

- 1.** Tarantino PA, Brockman EB, **Hobden JA**, Hill JM, O' Callaghan RJ, Kaufman HE: Keratotomy model of *Pseudomonas* keratitis: gentamicin chemotherapy. Invest Ophthalmol Vis Sci (Suppl) 32:1168, 1991 (ARVO Abstract).
- 2.** **Hobden JA**, O' Callaghan RJ, Hill JM, Hagenah M, Insler MS, Reidy JJ: Ciprofloxacin and prednisolone therapy for experimental *Pseudomonas* keratitis. Invest Ophthalmol Vis Sci (Suppl) 32:1184, 1991 (ARVO Abstract).
- 3.** O' Callaghan RJ, **Hobden JA**, Hill JM: Attenuated *Pseudomonas* and bacterial keratitis. Invest Ophthalmol Vis Sci (Suppl) 32:1183, 1991 (ARVO Abstract).
- 4.** Pendleton KM, **Hobden JA**, Hill JM, O' Callaghan RJ, Insler MS: Antibacterial activity of ciprofloxacin against organisms isolated from patients with bacterial keratitis. Invest Ophthalmol Vis Sci (Suppl) 32:1171, 1991 (ARVO Abstract).
- 5.** **Hobden JA**, Hill JM, O' Callaghan RJ: *Pseudomonas aeruginosa* keratitis: bacterial and host factors affecting pathogenicity. ASM South Central Branch Meeting, Jackson, Mississippi, 1991.
- 6.** Johnson MK, **Hobden JA**, Hagenah M, O' Callaghan RJ, Hill JM: Confirmation of the role of pneumolysin in ocular infections with *Streptococcus pneumoniae*. Invest Ophthalmol Vis Sci (Suppl) 33:1422, 1992 (ARVO Abstract).
- 7.** Callegan MC, **Hobden JA**, Hill JM, Insler MS, O' Callaghan RJ: Chemotherapy of methicillin-sensitive and methicillin-resistant *Staphylococcus aureus* keratitis in the rabbit. Invest Ophthalmol Vis Sci (Suppl) 33:935, 1992 (ARVO Abstract).
- 8.** Clinch TE, **Hobden JA**, Hill JM, O' Callaghan RJ, Kaufman HE: Sustained treatment of experimental *Pseudomonas* keratitis with collagen shields hydrated in tobramycin. Invest Ophthalmol Vis Sci (Suppl) 33:776, 1992 (ARVO Abstract).
- 9.** Bergsma Jr DR, **Hobden JA**, Hill JM, O' Callaghan RJ: Quantification of the immune response during bacterial keratitis. Invest Ophthalmol Vis Sci (Suppl) 33:1421, 1992 (ARVO Abstract).
- 10.** Hill JM, O' Callaghan RJ, **Hobden JA**, Reidy JJ: Antibacterial and anti-inflammatory agents for therapy of bacterial keratitis. 10th International Congress of Eye Research, Stresa, Italy, 1992.
- 11.** O' Callaghan RJ, **Hobden JA**, Hill JM: Corneal virulence of *Pseudomonas* mutants deficient in specific exoproteins. 10th International Congress of Eye Research, Stresa, Italy, 1992.
- 12.** Engel LS, Callegan MC, **Hobden JA**, Hill JM, O' Callaghan RJ: Differences in effectiveness of specific antibiotic/steroid combinations for the therapy of experimental *Pseudomonas aeruginosa* keratitis. Invest Ophthalmol Vis Sci (Suppl) 35:1339, 1994 (ARVO Abstract).
- 13.** **Hobden JA**, Hazlett LD: Aged mice fail to up-regulate ICAM-1 following *Pseudomonas aeruginosa* corneal infection. Invest Ophthalmol Vis Sci (Suppl) 36:S1059, 1995 (ARVO Abstract).
- 14.** Berk RS, Kernacki KA, **Hobden JA**, Hazlett LD, Fridman R: *P. aeruginosa* protease production in ocular tissue during corneal infection. Invest Ophthalmol Vis Sci (Suppl) 36:S1020, 1995 (ARVO Abstract).

15. Engel LS, O' Callaghan RJ, **Hobden JA**, Callegan MC, Hill JM: The role of protease and exotoxin A in *Pseudomonas aeruginosa* keratitis. Invest Ophthalmol Vis Sci (Suppl) 36:S1020, 1995 (ARVO Abstract).
16. Kernacki KA, **Hobden JA**, Hazlett LD, Fridman R, Berk RS: In vivo bacterial protease production during *P. aeruginosa* corneal infection. ASM General Meeting, Washington DC, 1995.
17. **Hobden JA**, Gupta Sk, Masinick SA, Wu X, Kernacki KA, Berk RS, Hazlett LD: Anti-receptor antibodies inhibit *P. aeruginosa* binding to the cornea and prevent corneal perforation. Invest Ophthalmol Vis Sci (Suppl) 37:S209, 1996 (ARVO Abstract).
18. Engel LS, Green LC, **Hobden JA**, Callegan MC, Hill JM, O' Callaghan RJ: Protease IV activity in vitro correlates with *Pseudomonas* corneal virulence in vivo. Invest Ophthalmol Vis Sci (Suppl) 37:S209, 1996 (ARVO Abstract).
19. Gupta SK, Masinick SA, **Hobden JA**, Berk RS, Hazlett LD: Role of bacterial protease in adherence of *P. aeruginosa* to mouse cornea. Invest Ophthalmol Vis Sci (Suppl) 37:S870, 1996 (ARVO Abstract).
20. **Hobden JA**, Masinick SA, Barrett RP, Hazlett LD: *Pseudomonas aeruginosa* keratitis in aged mice: role of cytokines. Invest Ophthalmol Vis Sci (Suppl) 38:S1137, 1997 (ARVO abstract).
21. O' Callaghan RJ, Engel LS, **Hobden JA**, Callegan MC, Moreau JM, Hill JM: Bacterial products responsible for tissue damage during bacterial keratitis. Invest Ophthalmol Vis Sci (Suppl) 38:S245, 1997 (ARVO abstract).
22. **Hobden JA**, Masinick SA, Barrett RP, Bark KS, Hazlett LD. *Pseudomonas aeruginosa* keratitis in mice deficient in intercellular adhesion molecule-1 expression. Invest Ophthalmol Vis Sci (Suppl) 39:S661, 1998 (ARVO abstract).
23. Alionte LG, Estrellas Jr. PS, **Hobden JA**. A *Pseudomonas aeruginosa* strain isolated from a contact lens-induced acute red eye is elastase-deficient. Invest Ophthalmol Vis Sci (Suppl) 39:S145, 1998 (ARVO abstract).
24. **Hobden JA**, Alionte LG, Estrellas Jr. PS. *Pseudomonas aeruginosa* staphylolytic protease and ocular virulence. Invest Ophthalmol Vis Sci (Suppl) 40:S259, 1999 (ARVO abstract).
25. Pillar CM, **Hobden JA**. The role of *Pseudomonas aeruginosa* alkaline protease in ocular infections. Invest Ophthalmol Vis Sci (Suppl) 40:S259, 1999 (ARVO abstract).
26. Kernacki KA, **Hobden JA**, Hazlett LD. MIP-2 expression correlates with PMN influx and tissue injury during *P. aeruginosa* corneal infection. Invest Ophthalmol Vis Sci (Suppl) 40:S793, 1999 (ARVO abstract).
27. Pillar CM, Hazlett LD, **Hobden JA**. The effect of *Pseudomonas aeruginosa* Alkaline Protease on Bacterial Adherence In Vitro. 1999 (ASM Abstract).
28. Somerville G, Hobden J, Reitzer L. Aconitase and the environmental signals that control virulence factor synthesis in *Pseudomonas aeruginosa*. Molecular Genetics of Bacteria and Phages, University of Wisconsin-Madison, 1999.
29. **Hobden JA**, Alionte LG, Cannon BM, White CD, Caballero AC, O' Callaghan RJ. *Pseudomonas aeruginosa* LasA protease and corneal infections. Invest Ophthalmol Vis Sci (Suppl) 41: S154, 2000 (ARVO abstract).
30. Pillar CM, Solem AC, **Hobden JA**. ICAM-2 and *Pseudomonas aeruginosa* keratitis. ASM General Meeting, Los Angeles, CA, 2000.

31. White CD, **Hobden JA**. The role of *Pseudomonas aeruginosa* staphylolytic protease (LasA) in adherence. ASM General Meeting, Los Angeles, CA, 2000.
32. **Hobden JA**. *Pseudomonas aeruginosa* proteases and corneal virulence. 14<sup>th</sup> International Congress of Eye Research, Santa Fe, NM, 2000.
33. Pillar CM, **Hobden JA**. *Pseudomonas aeruginosa* exotoxin A as a virulence factor in the eye. ASM General Meeting, Orlando, FL, 2001.
34. **Hobden JA**, Pillar CM. *Pseudomonas aeruginosa* exotoxin A and ocular virulence. Invest Ophthalmol Vis Sci (Suppl) 42:S739, 2001 (ARVO abstract).
35. **Hobden JA**, Liu G, Parks QM. Unraveling the ocular virulence of *Pseudomonas aeruginosa* gene by gene. 16<sup>th</sup> International Congress of Eye Research, Sydney, Australia, 2004.
36. Callegan MC, Moyer A, **Hobden JA**, Chodosh J. Effect of bacterial quorum-sensing on corneal cells *in vitro*. 16<sup>th</sup> International Congress of Eye Research, Sydney, Australia, 2004.
37. McCormick CC, Reed JM, **Hobden JA**, Caballero AR, O' Callaghan RJ. *Pseudomonas aeruginosa* keratitis in a surfactant –D knockout mouse model. MPIIER Meeting, Cleveland OH, 2005.
38. **Hobden JA**. Nona-D-arginine therapy for *P. aeruginosa* keratitis. MPIIER Meeting, Cleveland, OH, 2005.
39. Karicherla P, **Hobden JA**. Nona-D-arginine therapy for *Pseudomonas aeruginosa* keratitis. ARVO, 2007.
40. **Hobden JA**, Karicherla P. Nona-D-arginine therapy for *Pseudomonas aeruginosa* corneal disease. ICAAC/IDSA Annual Meeting, Washington, DC, 2008.
41. Dasa V, **Hobden JA**, Jacob JT, Lopez MJ, Krause PC, Hayes D. Bioresorbable, Nanocomposite Coatings Reduce Microbial Colonization of Orthopaedic Fixation Devices., Orthopedic Trauma Association Annual Meeting, Baltimore, MD, 2010.

Seminars & Other Invited Presentations:

1. Seminar, Pathogenesis of Bacterial Keratitis, Department of Biological Sciences, Loyola University, New Orleans, Louisiana, January 1993.
2. Seminar, Pathogenesis and Chemotherapy of *Pseudomonas aeruginosa* Keratitis, Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan, March 1993.
3. Seminar, *Pseudomonas aeruginosa* Exoproteins and Ocular Virulence, Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan, October, 1995.
4. Seminar, *Pseudomonas aeruginosa* Exoproteins and Ocular Virulence, Department of Biology, Eastern Michigan University, Ypsilanti, Michigan, October 2000.
5. Didactic Lecture, Update on *Pseudomonas* species, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, February 2001.
6. Newspaper interview on *Pseudomonas aeruginosa* corneal infections, The South End (Wayne State University campus paper), June 21, 2001.
7. Television Interview on Anthrax, WXYZ-TV (an ABC affiliate), Detroit, Michigan, October, 2001.

8. Community Forum on Bioterrorism, Sponsored by Wayne State University School of Medicine and the WSU Physician Group, Wayne State University Oakland Center, October 25, 2001 (filmed by ABC-affiliate WXYZ-TV for evening news coverage).
9. Newspaper Interview on Anthrax, Farmington Observer (Farmington, MI), November 1, 2001.
10. Seminar, Bioterrorism, St. Joseph Mercy-Oakland Post Clinic Day Conference, Pontiac, Michigan, November 14, 2001.
11. Seminar, Bioterrorism, Birmingham Senior Mens Club, Birmingham, Michigan, January 18, 2002.
12. Newspaper Interview on Bioterrorism, Oakland Press (Oakland County, MI), January 12, 2003.
13. Seminar, *Pseudomonas aeruginosa* Corneal Disease: Both Sides Now, Department of Microbiology, Medical College of Ohio, Toledo, Ohio, January 22, 2003.
14. Seminar, Bioterrorism, Violence Awareness Week, Wayne State University School of Medicine, Detroit, Michigan, January 29, 2003.
15. Seminar, New Technologies for Examining Host-Pathogen Interactions, Michigan Branch American Society for Microbiology Spring 2003 Meeting, Pfizer Corp., Ann Arbor, Michigan, April 5, 2003.
16. Invited presentation, *Pseudomonas aeruginosa* and Corneal Virulence, 10th Annual Midwest Pathogenesis Meeting, October 2003, Iowa City, Iowa.
17. Seminar, The Molecular Pathogenesis of *Pseudomonas aeruginosa* Corneal Infections, Dept. of Biological Sciences, Loyola University, New Orleans, Louisiana, November 16, 2004.
18. Seminar, *Pseudomonas aeruginosa* Keratitis: You are Your Own Worst Enemy, Infectious Diseases Section, Dept. of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, April 5, 2007.
19. Seminar, Infectious Diseases of the Cornea, Citywide Rounds, Ochsner Foundation Hospital, New Orleans, Louisiana, November, 2007.
20. Television Interview on Lemons and Bacterial Contamination, WVUE-TV (a FOX affiliate), New Orleans, LA, April, 2008.
21. Television Interview on Health Implications and Drinking Human Blood, ABC Primetime News, New Orleans, LA, June 2009.
22. Television Interview on Bioscience Education & Training Program, WWL-TV (a CBS affiliate), New Orleans, LA, August, 2009.
23. Seminar, Oral Presentations and Lecture Skills, Professional Advancement for Clinical Educators – House Officer Professionalism Education (PACE-HOPE series), Dept. of Medicine and Office of Medical Education Research and Development, LSU Health Sciences Center, New Orleans, Louisiana, August 19, 2009.

**Editorial Posts and Activities:**

- |              |   |
|--------------|---|
| 1988-1989    | Section Editor of the Murmur (LSU Medical Center's yearbook), Louisiana State University Medical Center, New Orleans, Louisiana.  |
| 1996-present | Ad Hoc reviewer for journals Antimicrobial Agents and Chemotherapy, Cornea, Current Eye Research, Infection and Immunity, Investigative Ophthalmology and Visual Science, Journal of Clinical Microbiology, Journal of Immunology, Ophthalmology, and Pediatric Drugs |

2002- present Guest editorial board member for Investigative Ophthalmology and Visual Science.

**University/Institutional Service:**

Departmental Committees:

- 1997-1998, Salary Committee, Department of Immunology and Microbiology,  
2000-2001 Wayne State University School of Medicine, Detroit, Michigan.  
1998- 2003 Graduate Committee Chair, Department of Immunology and  
Microbiology, Wayne State University School of Medicine, Detroit,  
Michigan.  
1998- 2004 Space Committee, Department of Immunology and Microbiology,  
Wayne State University School of Medicine, Detroit, Michigan.  
2006- present Curriculum Committee, Louisiana State University Health Sciences  
Center, New Orleans, Louisiana.  
2006- present Hurricane Preparedness Committee, Louisiana State University Health  
Sciences Center, New Orleans, Louisiana.

School of Medicine Committees:

- 1988-1990 Graduate Student Council, School of Graduate Studies, Louisiana State  
University Medical Center, New Orleans, Louisiana.  
1988-1990 Health Promotion Committee, Louisiana State University Medical Center,  
New Orleans, Louisiana.  
1996 Postdoctoral Enhancement Committee, Wayne State University School of  
Medicine, Detroit, Michigan.  
2001-2003 Interdisciplinary Biological Sciences Stipend Committee, Wayne State  
University School of Medicine, Detroit, Michigan.  
2001-2003 Graduate Affairs Council, Wayne State University School of Medicine,  
Detroit, MI.  
2005- 2010 Graduate Affairs Council, Louisiana State University Health Sciences  
Center, New Orleans, Louisiana.  
2006- present Faculty Senate alternate, Louisiana State University Health Sciences  
Center, New Orleans, Louisiana.  
2008- present Pre-clinical Promotions Committee, Louisiana State University Health  
Sciences Center, New Orleans, Louisiana.  
2008-2009 LCME Self Study on Education Committee, Louisiana State University  
Health Sciences Center, New Orleans, Louisiana.  
2009-present Curriculum Oversight Committee, Louisiana State University Health  
Sciences Center, New Orleans, Louisiana.

Professional Societies Committees:

- 1989 Student Science Day Committee, American Society for Microbiology  
Annual Meeting, New Orleans, Louisiana.  
2000 Microbiology Co-Chair, International Science and Engineering Fair  
(ISEF), Detroit, Michigan.

### **Administrative Responsibilities:**

#### **Departmental:**

- 2001-2003 Graduate Officer, Department of Microbiology and Immunology, Wayne State University School of Medicine, Detroit, MI.
- 2005-2010 Co-graduate coordinator, Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana.

### **Community Service/Activities:**

- 1999-2003 Mentor, Math and Science Program, Cranbrook Institute of Science, Bloomfield Hills, Michigan.
- 2005-present Judge, Undergraduate Research Symposium, Loyola University, New Orleans, Louisiana.
- 2005 Mentor (Angie Serrano), Science Fair, John Ehret High School, Marrero, Louisiana.
- 2004- present Online mentor, ASM Minority Mentoring Program, American Society for Microbiology.
- 2009 Expert Witness for the State of Louisiana in lawsuit against the LA DOTD, case settled out of court after deposition (estimated savings to LA = \$250,000).
- 2009 Judge, Phi Zeta Research Day, LSU School of Veterinary Medicine, Baton Rouge, Louisiana.
- 2010 Mentor (Srihasa Allam), High School Summer Research Internship, LSU Health Sciences Center.

### **Books & Chapters:**

1. Hill JM, **Hobden JA**, Liu WG, Wen R, Zhang X, Callegan MC: Ocular Antivirals. In International Ophthalmology Clinics, vol 33, no 4, Smolin G, Friedlaender MH (eds), Little Brown and Co., Boston, pg. 69-80, 1993.
2. Hill JM, O' Callaghan RJ, **Hobden JA**, Kaufman HE: Corneal Collagen Shields for Ocular Delivery. In Ophthalmic Drug Delivery Systems, Mitra AK (ed), Marcel Dekker Inc., New York, pg. 261-273, 1993.
3. Hill JM, O' Callaghan RJ, **Hobden JA**: Ocular Iontophoresis. In Ophthalmic Drug Delivery Systems, Mitra AK (ed), Marcel Dekker Inc., New York, pg. 331-354, 1993.
4. Kernacki KA, **Hobden JA**, Hazlett LD: Murine Model of Keratitis. In Handbook of Animal Models of Infection, Sak O, Sande M (eds), Academic Press, Ltd., London, pg. 361-366, 1999.
5. Hill JM, Denham LV, Booth BA, Friedman DA, **Hobden JA**, Murina AT, Aciemo MD, Jacob JT, Kaufman HE, Bergsma DR : Ophthalmic Pharmacology. In Color Atlas of Ophthalmology, Mandava S, Sweeney T, Guyer D (eds), Thieme Medical Publishers, New York, NY, pg. 405-429, 2009.

### **Journal Publications (all in refereed journals):**

1. Rootman DS, **Hobden JA**, Jantzen JA, Gonzales JR, O' Callaghan RJ, Hill JM: Iontophoresis of tobramycin for the treatment of experimental *Pseudomonas aeruginosa* keratitis in the rabbit. Arch Ophthalmol 106:262-265, 1988.

2. **Hobden JA**, Rootman DS, O' Callaghan RJ, Hill JM: Iontophoretic application of tobramycin to uninfected and *Pseudomonas aeruginosa*-infected rabbit corneas. *Antimicrob Agents Chemother* 32:978-981, 1988.
3. **Hobden JA**, Reidy JJ, O' Callaghan RJ, Hill JM, Insler MS, Rootman DS: Treatment of experimental *Pseudomonas* keratitis using collagen shields containing tobramycin. *Arch Ophthalmol* 106:1605-1607, 1988.
4. **Hobden JA**, O' Callaghan RJ, Hill JM, Reidy JJ, Rootman DS, Thompson HW: Tobramycin iontophoresis into corneas infected with drug-resistant *Pseudomonas* keratitis. *Curr Eye Res* 11:1163-1169, 1988.
5. **Hobden JA**, Reidy JJ, O' Callaghan RJ, Insler MS, Hill JM: Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. *Invest Ophthalmol Vis Sci* 31:1940-1944, 1990.
6. **Hobden JA**, Reidy JJ, O'Callaghan RJ, Insler MS, Hill JM: Quinolones in collagen shields to treat aminoglycoside-resistant pseudomonal keratitis. *Invest Ophthalmol Vis Sci* 31:2241-2243, 1990.
7. Johnson MK, **Hobden JA**, Hagenah M, O'Callaghan RJ, Hill JM, Chen S: The role of pneumolysin in ocular infections with *Streptococcus pneumoniae*. *Curr Eye Res* 9:1107-1114, 1990.
8. Reidy JJ, **Hobden JA**, Hill JM, Forman K, O' Callaghan RJ: The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental *Pseudomonas* keratitis. *Cornea* 10:25-28, 1991.
9. Insler MS, Fish LA, Silbernagel J, **Hobden JA**, Hill JM, O' Callaghan RJ, Insler MS, Kaufman HE: Treatment of methicillin-resistant *Staphylococcus aureus* keratitis with topical ciprofloxacin. *Ophthalmology* 98:1690-1692, 1991.
10. Brockman EB, Tarantino PA, **Hobden JA**, Hill JM, O' Callaghan RJ, Insler MS, Kaufman HE: Keratotomy model of *Pseudomonas* keratitis: gentamicin chemotherapy. *Refract Corneal Surg* 8:465-468, 1992.
11. Callegan MC, Hill JM, Insler MS, **Hobden JA**, O'Callaghan RJ: Methicillin-resistant *Staphylococcus aureus* keratitis in the rabbit: therapy with ciprofloxacin, vancomycin, and cefazolin. *Curr Eye Res* 11:1111-1119, 1992.
12. Clinch TE, **Hobden JA**, Hill JM, Insler MS, O' Callaghan RJ, Engel LS, Kaufman HE: Experimental *Pseudomonas* keratitis: therapy with tobramycin-hydrated collagen shields. *CLAO J* 18:245-247, 1992.
13. Callegan MC, **Hobden JA**, Hill JM, Insler MS, O'Callaghan RJ: Topical antibiotic therapy for the treatment of experimental *Staphylococcus aureus* keratitis. *Invest Ophthalmol Vis Sci* 33:3017-3023, 1992.
14. **Hobden JA**, O' Callaghan RJ, Hill JM, Hagenah M, Insler MS, Reidy JJ: Ciprofloxacin and prednisolone therapy for experimental *Pseudomonas* keratitis. *Curr Eye Res* 11:259-266, 1992.
15. Johnson MK, Hobden JA, O' Callaghan RJ, Hill JM: Confirmation of the role of pneumolysin in ocular infections with *Streptococcus pneumoniae*. *Curr Eye Res* 11:1221-1225, 1992.
16. **Hobden JA**, O' Callaghan RJ, Insler MS, Hill JM: Ciprofloxacin ointment versus topical drops for the therapy of experimental *Pseudomonas* keratitis. *Cornea* 12:138-141, 1993.

17. **Hobden JA**, Engel LS, Hill JM, O' Callaghan RJ: Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental *Pseudomonas aeruginosa* keratitis. *Curr Eye Res* 12:469-473, 1993.
18. **Hobden JA**, Engel LS, Hill JM, O' Callaghan RJ: *Pseudomonas aeruginosa* keratitis in leukopenic rabbits. *Curr Eye Res* 12:461-467, 1993.
19. **Hobden JA**, Hill JM, Insler MS, O' Callaghan RJ: Age and the therapeutic outcome of experimental *Pseudomonas aeruginosa* keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen. *Antimicrob Agents Chemother* 37:1856-1859, 1993.
20. **Hobden JA**, Masinick SA, Barrett RP, Hazlett LD: Aged mice fail to up-regulate ICAM-1 following *Pseudomonas aeruginosa* corneal infection. *Invest Ophthalmol Vis Sci* 36:1107-1114, 1995.
21. Engel LS, Callegan MC, **Hobden JA**, Reidy JJ, Hill JM, O' Callaghan RJ: Effectiveness of specific antibiotic/steroid combinations for therapy of experimental *Pseudomonas aeruginosa* keratitis. *Curr Eye Res* 14:229-234, 1995.
22. Kernacki KA, Fridman R, **Hobden JA**, Hazlett LD, Berk RS: In vivo bacterial protease production during *Pseudomonas aeruginosa* corneal infection. *Invest Ophthalmol Vis Sci* 36:1371-1378, 1995.
23. Johnson MK, Callegan MC, Engel LS, O' Callaghan RJ, Hill JM, **Hobden JA**, Boulnois GJ, Andrew PW, Mitchell TJ: Growth and virulence of a complement-activation-negative mutant of *Streptococcus pneumoniae* in the rabbit cornea. *Curr Eye Res* 14:281-284, 1995.
24. Callegan MC, **Hobden JA**, O' Callaghan RJ, Hill JM: Ocular drug delivery: a comparison of transcorneal iontophoresis to corneal collagen shields. *Int J Pharmaceutics* 123:173-179, 1995.
25. O' Callaghan RJ, Engel LS, **Hobden JA**, Callegan MC, Green LC, Hill JM: *Pseudomonas* keratitis: the role of an uncharacterized exoprotein, protease IV, in corneal virulence. *Invest Ophthalmol Vis Sci* 37: 534-543, 1996.
26. Gupta SK, Masinick SA, **Hobden JA**, Berk RS, Hazlett LD: Bacterial proteases and adherence of *Pseudomonas aeruginosa* to mouse cornea. *Exp Eye Res* 62:641-650, 1996.
27. **Hobden JA**, Gupta SK, Masinick SA, Wu X, Kernacki KA, Berk RS, Hazlett LD: Anti-receptor antibodies inhibit *P. aeruginosa* binding to the cornea and prevent corneal perforation. *Immunol Cell Biol* 74:258-264, 1996.
28. Engel LS, **Hobden JA**, Moreau JM, Callegan MC, Hill JM, O' Callaghan RJ: *Pseudomonas* deficient in protease IV has significantly reduced corneal virulence. *Invest Ophthalmol Vis Sci* 38:1535-1542, 1997.
29. **Hobden JA**, Masinick SA, Barrett RP, Hazlett LD: Proinflammatory cytokine deficiency and the pathogenesis of *Pseudomonas aeruginosa* keratitis in aged mice. *Infect Immun* 65: 2754-2758, 1997.
30. Engel LS, Hill JM, Moreau JM, Green LC, **Hobden JA**, O'Callaghan RJ: *Pseudomonas aeruginosa* protease IV produces corneal damage and contributes to bacterial virulence. *Invest Ophthalmol Vis Sci* 39:662-665, 1998.
31. Chen L, **Hobden JA**, Masinick SA, Hazlett, LD: Environmental factors influence *P. aeruginosa* binding to wounded mouse cornea. *Curr Eye Res* 17:231-237, 1998.

32. Cowell BA, Willcox MDP, **Hobden JA**, Schneider RP, Tout S, Hazlett LD: An ocular strain of *Pseudomonas aeruginosa* is inflammatory but not virulent in the scarified mouse model. *Exp Eye Res* 67:347-356, 1998.
33. **Hobden JA**, Masinick-McClellan SA, Barrett RP, Bark KS, Hazlett LD: *Pseudomonas aeruginosa* keratitis in knockout mice deficient in intercellular adhesion molecule-1 (ICAM-1) expression. *Infect Immun* 67:972-975, 1999.
34. Kernacki KA, Barrett RP, **Hobden JA**, Hazlett LD: MIP-2 is a major mediator of PMN influx in ocular bacterial infection, *J Immunol* 164:1037-1045, 2000.
35. Estrellas PS, Jr., Alionte LG, **Hobden JA**: A *Pseudomonas aeruginosa* strain isolated from a contact lens-induced acute red eye (CLARE) is protease-deficient. *Curr Eye Res* 20: 157-165, 2000.
36. Pillar CM, Hazlett LD, **Hobden JA**: Alkaline protease-deficient mutants of *Pseudomonas aeruginosa* are virulent in the eye. *Curr Eye Res* 21:730-739, 2000.
37. Alionte LG, Cannon B, White CD, Caballero AC, O' Callaghan RJ, **Hobden JA**: *Pseudomonas aeruginosa* LasA protease and corneal infections. *Curr Eye Res* 22: 266-271, 2001.
38. White CD, Alionte LG, Cannon B, Caballero AC, O' Callaghan RJ, **Hobden JA**: *Pseudomonas aeruginosa* PAO1 LasA protease and ocular virulence. *Cornea* 20:643-646, 2001.
39. Pillar CM, **Hobden JA**: *Pseudomonas aeruginosa* exotoxin A and keratitis in mice. *Invest Ophthalmol Vis Sci* 43: 1437-1444, 2002.
40. **Hobden JA**: *Pseudomonas aeruginosa* proteases and corneal virulence. *DNA and Cell Biol* 21: 391-396, 2002
41. Cowell BA, Twining SS, **Hobden JA**, Kwong MSF, Fleiszig SMJ: Mutation of LasA and LasB inhibits *Pseudomonas aeruginosa* invasion of epithelial cells. *Microbiology* 149: 2291-2299, 2003.
42. **Hobden JA**: Intercellular Adhesion Molecule-2 (ICAM-2) and *Pseudomonas aeruginosa* Ocular Infection. *DNA and Cell Biol* 22: 649-655, 2003.
43. Thakur A, Barrett RP, **Hobden JA**, Hazlett LD: Caspase-1 inhibitor reduces severity of *Pseudomonas aeruginosa* keratitis in mice. *Invest Ophthalmol Vis Sci*, 45: 3177-3184, 2004.
44. Parks QM, **Hobden JA**: Polyphosphate kinase 1 and the ocular virulence of *Pseudomonas aeruginosa*. *Invest Ophthalmol Vis Sci* 46: 248-251, 2005.
45. McCormick CC, **Hobden JA**, Balzli CL, Reed JM, Caballero AR, Denard BS, Tang A, O' Callaghan RJ: Surfactant protein D in *Pseudomonas aeruginosa* keratitis. *Ocular Immunol Inflamm* 15: 1-9, 2007.
46. Karicherla P, **Hobden JA**. Nona-D-Arginine therapy for *Pseudomonas aeruginosa* keratitis. *Invest Ophthalmol Vis Sci*, 50:256-262, 2009.
47. Karicherla P, **Hobden JA**. Nona-D-arginine amide for prophylaxis and treatment of experimental *Pseudomonas aeruginosa* keratitis. *Curr. Eye Res*, 35:220-224, 2010.
49. Karicherla P, Aras S, Airyar A, **Hobden JA**. Nona-D-arginine amide (D9R) suppresses corneal cytokines in *Pseudomonas aeruginosa* keratitis. *Cornea*, in press, 2010.
50. **Hobden JA**, Kumar M, Kaufman HE, Clement C, Varnell ED, Bhattacharjee PS, Hill JM. Triflurothymidine and Ganciclovir are Synergistic against HSV- 1. *Invest Ophthalmol Vis Sci*, submitted, 2010.

**51.** Clement C, Capriotti JA, Kumar M, **Hobden JA**, Foster TP, Bhattacharjee PS, Thompson H, Mahmud R, Liang B, Hill JM. Clinical and Antiviral Efficacy of an Ophthalmic Formulation of Dexamethasone Povidone-Iodine in a Rabbit Model of Adenoviral Keratoconjunctivitis. *Invest Ophthalmol Vis Sci*, submitted, 2010.

**51.** Karicherla P, **Hobden JA**. Nona-D-arginine amide enhances the killing of *Pseudomonas aeruginosa*. *J of Ocular Pharm. Ther.*, in preparation, 2010.